Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688273's EV-to-FCF is ranked worse than 93.48% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.2
vs SHSE:688273: 246.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanjing Medlander Medical Technology Co (SHSE:688273) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanjing Medlander Medical Technology Co's PE Ratio (TTM) for today is calculated as:
Nanjing Medlander Medical Technology Co's share price for today is ¥29.17.
Nanjing Medlander Medical Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.876.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nanjing Medlander Medical Technology Co EV-to-FCF Related Terms
Nanjing Medlander Medical Technology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co EV-to-FCF Chart
Nanjing Medlander Medical Technology Co Annual Data
SHSE:688273 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Medlander Medical Technology Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nanjing Medlander Medical Technology Co's EV-to-FCF falls into.
Nanjing Medlander Medical Technology Co's current Enterprise Value is ¥2,187.3 Mil.
Nanjing Medlander Medical Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥8.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co (SHSE:688273) has a EV-to-FCF of 246.76 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nanjing Medlander Medical Technology Co and its competitors. This is 1174% above median its historical median of 19.37. According to the industry distribution chart, Nanjing Medlander Medical Technology Co ranks #387 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 93.5%.
Is Nanjing Medlander Medical Technology Co's EV-to-FCF too high?
Nanjing Medlander Medical Technology Co's current EV-to-FCF of 246.76 is 1174% above median its 10-year median of 19.37. The Medical Devices & Instruments industry median EV-to-FCF is 23.20. Nanjing Medlander Medical Technology Co's value of 246.76 is 963.6% above this industry median. Based on the distribution chart, Nanjing Medlander Medical Technology Co ranks #387 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Medlander Medical Technology Co ranks #387 out of 414 companies for EV-to-FCF. This places Nanjing Medlander Medical Technology Co in the lower half of its industry. The industry median EV-to-FCF is 23.20. Nanjing Medlander Medical Technology Co's value of 246.76 is 963.6% above this benchmark. While the company's 10-year median is 19.37 vs. the industry median of 23.20, Nanjing Medlander Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.20, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Medlander Medical Technology Co's current EV-to-FCF of 246.76 is 963.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nanjing Medlander Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Medlander Medical Technology Co's current EV-to-FCF is 246.76, which is 1174% above median its own 10-year median of 19.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥35.59, compared to a current price of ¥29.17 — trading 18% below its estimated fair value. The current EV-to-FCF is 246.76, which is 1174% above median its 10-year median of 19.37 and 963.6% above the Medical Devices & Instruments industry median of 23.20. Nanjing Medlander Medical Technology Co's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current EV-to-FCF is 246.76 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be undervalued.
The current stock price of ¥29.17 is trading 18% below its estimated GF Value™ of ¥35.59.
GuruFocus considers Nanjing Medlander Medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688273:
EV-to-FCF: 246.76 (1174% above median its 10-year median of 19.37)
GF Value™: ¥35.59 vs. price of ¥29.17 (18% below fair value)
Industry Position: 963.6% above the Medical Devices & Instruments median (#387 of 414)
No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Medlander Medical Technology Co Business Description
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
81GF Score
Get the complete analysis for SHSE:688273
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688273 has been successfully added to your 
